Prognosis of hepatitis B virus reactivation in newly diagnosed multiple myeloma in modern era therapy: a retrospective study

Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HB...

Full description

Saved in:
Bibliographic Details
Published inPeerJ (San Francisco, CA) Vol. 12; p. e18475
Main Authors Lv, Weiran, Li, Xiaojin, Xu, Jingbo, Wang, Yun, Huang, Hanying, Hu, Fang, Cui, Yingying, Song, Yuanbin, Chen, Lezong, Wu, Bingyi, Liang, Yang
Format Journal Article
LanguageEnglish
Published United States PeerJ. Ltd 01.11.2024
PeerJ Inc
Subjects
Adult
Aged
Bortezomib - therapeutic use
Female
Gastroenterology and Hepatology
Health aspects
Hematology
Hepatitis B - drug therapy
Hepatitis B - virology
Hepatitis B Surface Antigens - blood
Hepatitis B virus
Hepatitis B virus - physiology
Humans
Infectious Diseases
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Multiple Myeloma - virology
Oncology
Prevention
Prognosis
Reactivation
Retrospective Studies
Risk Factors
Statistics
Virology
Virus Activation
China
Reactivation
Prognosis
Hepatitis B virus
Multiple myeloma
Online AccessGet full text

Cover

Abstract Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HBV reactivation were included in this study. Multivariable analysis showed that hepatitis B surface antigen-positivity, hepatitis B core antibody-positivity, bortezomib-containing regimens, autologous stem cell transplantation, and gain of 1q21 were identified as independent risk factors of HBV reactivation in NDMM patients. The NDMM patients with HBV reactivation had poorer 3-year overall survival (OS) and progression-free survival (PFS) than did those without HBV reactivation, as confirmed by multivariate analysis. In conclusion, HBV reactivation in patients with NDMM constitutes a significant complication, correlating with reduced OS and PFS, and emerges as a potential adverse prognostic factor in the contemporary era of treatment.
AbstractList Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HBV reactivation were included in this study. Multivariable analysis showed that hepatitis B surface antigen-positivity, hepatitis B core antibody-positivity, bortezomib-containing regimens, autologous stem cell transplantation, and gain of 1q21 were identified as independent risk factors of HBV reactivation in NDMM patients. The NDMM patients with HBV reactivation had poorer 3-year overall survival (OS) and progression-free survival (PFS) than did those without HBV reactivation, as confirmed by multivariate analysis. In conclusion, HBV reactivation in patients with NDMM constitutes a significant complication, correlating with reduced OS and PFS, and emerges as a potential adverse prognostic factor in the contemporary era of treatment.
Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HBV reactivation were included in this study. Multivariable analysis showed that hepatitis B surface antigen-positivity, hepatitis B core antibody-positivity, bortezomib-containing regimens, autologous stem cell transplantation, and gain of 1q21 were identified as independent risk factors of HBV reactivation in NDMM patients. The NDMM patients with HBV reactivation had poorer 3-year overall survival (OS) and progression-free survival (PFS) than did those without HBV reactivation, as confirmed by multivariate analysis. In conclusion, HBV reactivation in patients with NDMM constitutes a significant complication, correlating with reduced OS and PFS, and emerges as a potential adverse prognostic factor in the contemporary era of treatment.Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HBV reactivation were included in this study. Multivariable analysis showed that hepatitis B surface antigen-positivity, hepatitis B core antibody-positivity, bortezomib-containing regimens, autologous stem cell transplantation, and gain of 1q21 were identified as independent risk factors of HBV reactivation in NDMM patients. The NDMM patients with HBV reactivation had poorer 3-year overall survival (OS) and progression-free survival (PFS) than did those without HBV reactivation, as confirmed by multivariate analysis. In conclusion, HBV reactivation in patients with NDMM constitutes a significant complication, correlating with reduced OS and PFS, and emerges as a potential adverse prognostic factor in the contemporary era of treatment.
ArticleNumber e18475
Audience Academic
Author Wu, Bingyi
Hu, Fang
Song, Yuanbin
Xu, Jingbo
Huang, Hanying
Chen, Lezong
Liang, Yang
Li, Xiaojin
Lv, Weiran
Cui, Yingying
Wang, Yun
Author_xml – sequence: 1
  givenname: Weiran
  surname: Lv
  fullname: Lv, Weiran
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 2
  givenname: Xiaojin
  surname: Li
  fullname: Li, Xiaojin
  organization: Hematology, Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, China
– sequence: 3
  givenname: Jingbo
  surname: Xu
  fullname: Xu, Jingbo
  organization: Hematology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China
– sequence: 4
  givenname: Yun
  surname: Wang
  fullname: Wang, Yun
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 5
  givenname: Hanying
  surname: Huang
  fullname: Huang, Hanying
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 6
  givenname: Fang
  surname: Hu
  fullname: Hu, Fang
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 7
  givenname: Yingying
  surname: Cui
  fullname: Cui, Yingying
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 8
  givenname: Yuanbin
  surname: Song
  fullname: Song, Yuanbin
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 9
  givenname: Lezong
  surname: Chen
  fullname: Chen, Lezong
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 10
  givenname: Bingyi
  surname: Wu
  fullname: Wu, Bingyi
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
– sequence: 11
  givenname: Yang
  surname: Liang
  fullname: Liang, Yang
  organization: Hematology, Sun Yat-sen University Cancer Center, Guangzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39498289$$D View this record in MEDLINE/PubMed
BookMark eNptkttrFDEUxgep2Fr75LsEBBFk12Qyl6QvUouXQkEf9DlkkpPdLJnJmGRWFvzjzezWsgsmkMvJ73ycQ77nxdngByiKlwQv25a070eAsFkSVrX1k-KiJE27YLTmZ0fn8-Iqxg3Og5UNZvRZcU55xVnJ-EXx53vwq8FHG5E3aA2jTDbly0e0tWGKKIBUyW5z1A_IDmiA326HtJVzEmjUTy7Z0QHqd-B8L2em9xrCgCBIlNZ5HXfXSGalFHwcYZYDFNOkdy-Kp0a6CFcP-2Xx8_OnH7dfF_ffvtzd3twvVI2rtOgqhhtiSqNqomiHKZXAgUmjoKtxLbHqiGpLbWhFKoIlwbjkDVcNN9zopqGXxd1BV3u5EWOwvQw74aUV-4APKyFDssqB6GogujLAc16ljWKckpbhUtatzjXwrPXhoDVOXQ9awZCCdCeipy-DXYuV3wpCako5nqt5-6AQ_K8JYhK9jQqckwP4KQpKyoqULSnrjL4-oCuZa7OD8VlSzbi4YaSqMCO4zdTyP1SeGnqrsl-MzfGThDdHCWuQLq2jd9P8yfEUfHXc7GOX__yTgXcHQOW_jQHMI0KwmA0q9gYVe4PSv41Z2W8
Cites_doi 10.1182/blood.V98.10.2992
10.1158/1078-0432.CCR-16-0625
10.1586/eri.11.79
10.1007/s00277-016-2742-7
10.1016/S0016-5085(75)80054-0
10.1038/sj.bjc.6601699
10.3109/10428194.2014.941833
10.3892/ol.2019.10926
10.1002/ajh.24857
10.3109/10428194.2011.610013
10.3390/cancers11111819
10.1016/j.jceh.2015.06.002
10.1093/annonc/mdx694
10.1200/JCO.2008.18.0182
10.1111/liv.12838
10.1111/j.1365-2141.2007.06705.x
10.1002/hep.22945
10.1016/j.cld.2016.06.005
10.1038/ni.3159
10.1182/blood-2007-10-116129
10.1016/j.clinre.2011.07.018
10.1002/(ISSN)1096-9071
10.3389/fimmu.2020.00552
10.1038/s41408-017-0002-2
10.1002/ajh.23932
10.1086/605664
10.4274/tjh.galenos.2019.2019.0103
10.1007/s12253-015-0014-9
10.1111/j.1872-034X.2012.00998.x
10.1046/j.1365-2141.2003.04355.x
ContentType Journal Article
Copyright 2024 Lv et al.
COPYRIGHT 2024 PeerJ. Ltd.
2024 Lv et al. 2024 Lv et al.
Copyright_xml – notice: 2024 Lv et al.
– notice: COPYRIGHT 2024 PeerJ. Ltd.
– notice: 2024 Lv et al. 2024 Lv et al.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.7717/peerj.18475
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals (WRLC)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Statistics
EISSN 2167-8359
ExternalDocumentID oai_doaj_org_article_b5e1d4fe9d664dfc89317802a57d61f9
PMC11533906
A814408107
39498289
10_7717_peerj_18475
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Sun Yat-sen University Start-up Funding
  grantid: 201603
– fundername: Basic and Applied Basic Research Foundation of Guangdong Province
  grantid: 2022A1515110503
GroupedDBID 53G
5VS
88I
8FE
8FH
AAFWJ
AAYXX
ABUWG
ADBBV
ADRAZ
AENEX
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
ECGQY
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HYE
IAO
IEA
IHR
IHW
ITC
KQ8
LK8
M2P
M48
M7P
M~E
OK1
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
W2D
YAO
CGR
CUY
CVF
ECM
EIF
H13
NPM
PQGLB
PMFND
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c504t-b48061f2fc51c3b033ae9e8afceb505a0cb1c72df341410a1002969c69f9fd663
IEDL.DBID M48
ISSN 2167-8359
IngestDate Wed Aug 27 01:28:13 EDT 2025
Thu Aug 21 18:43:53 EDT 2025
Fri Jul 11 15:12:24 EDT 2025
Tue Jun 17 22:01:33 EDT 2025
Tue Jun 10 21:02:47 EDT 2025
Thu May 22 21:22:49 EDT 2025
Mon Jul 21 06:05:59 EDT 2025
Tue Jul 01 02:28:58 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Reactivation
Prognosis
Hepatitis B virus
Multiple myeloma
Language English
License https://creativecommons.org/licenses/by-nc/4.0
2024 Lv et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits using, remixing, and building upon the work non-commercially, as long as it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c504t-b48061f2fc51c3b033ae9e8afceb505a0cb1c72df341410a1002969c69f9fd663
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.7717/peerj.18475
PMID 39498289
PQID 3124127125
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_b5e1d4fe9d664dfc89317802a57d61f9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11533906
proquest_miscellaneous_3124127125
gale_infotracmisc_A814408107
gale_infotracacademiconefile_A814408107
gale_healthsolutions_A814408107
pubmed_primary_39498289
crossref_primary_10_7717_peerj_18475
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-11-01
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Diego, USA
PublicationTitle PeerJ (San Francisco, CA)
PublicationTitleAlternate PeerJ
PublicationYear 2024
Publisher PeerJ. Ltd
PeerJ Inc
Publisher_xml – name: PeerJ. Ltd
– name: PeerJ Inc
References Andersen (10.7717/peerj.18475/ref-1) 2017; 92
Tsukune (10.7717/peerj.18475/ref-25) 2016; 2016
Hoofnagle (10.7717/peerj.18475/ref-8) 2019; 49
Wands (10.7717/peerj.18475/ref-27) 1975; 68
Atilla (10.7717/peerj.18475/ref-3) 2019; 18, 36
International Myeloma Working Group (10.7717/peerj.18475/ref-11) 2003; 121
Kumar (10.7717/peerj.18475/ref-12) 2008; 111
Stasi (10.7717/peerj.18475/ref-23) 2017; 5
Anderson (10.7717/peerj.18475/ref-2) 2016; 22
Huang (10.7717/peerj.18475/ref-9) 2012; 53
Yeo (10.7717/peerj.18475/ref-30) 2000; 62
Brown (10.7717/peerj.18475/ref-4) 2001; 98
Oketani (10.7717/peerj.18475/ref-18) 2012; 42
Sallberg (10.7717/peerj.18475/ref-22) 2020; 11
Holmstrom (10.7717/peerj.18475/ref-7) 2015; 90
Yeo (10.7717/peerj.18475/ref-31) 2004; 90
Kwok (10.7717/peerj.18475/ref-13) 2016; 20
Lee (10.7717/peerj.18475/ref-14) 2015; 35
Pratt (10.7717/peerj.18475/ref-20) 2007; 138
Tsukune (10.7717/peerj.18475/ref-26) 2017; 7
R Core Team (10.7717/peerj.18475/ref-21) 2022
Papamichalis (10.7717/peerj.18475/ref-19) 2012; 36
Nucci (10.7717/peerj.18475/ref-17) 2009; 49
Guo (10.7717/peerj.18475/ref-6) 2019; 18
Lin (10.7717/peerj.18475/ref-16) 2017; 29
Tsukune (10.7717/peerj.18475/ref-24) 2019; 11
Carretero (10.7717/peerj.18475/ref-5) 2015; 16
Wang (10.7717/peerj.18475/ref-28) 2016; 22
Li (10.7717/peerj.18475/ref-15) 2015; 56
Idilman (10.7717/peerj.18475/ref-10) 2011; 9
Yeo (10.7717/peerj.18475/ref-29) 2009; 27
References_xml – volume: 98
  start-page: 2992
  issue: 10
  year: 2001
  ident: 10.7717/peerj.18475/ref-4
  article-title: Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10
  publication-title: Blood
  doi: 10.1182/blood.V98.10.2992
– volume: 22
  start-page: 5419
  issue: 22
  year: 2016
  ident: 10.7717/peerj.18475/ref-2
  article-title: Progress and paradigms in multiple myeloma
  publication-title: Clinical Cancer Research
  doi: 10.1158/1078-0432.CCR-16-0625
– volume: 9
  start-page: 641
  issue: 8
  year: 2011
  ident: 10.7717/peerj.18475/ref-10
  article-title: Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation
  publication-title: Expert Review of Anti-infective Therapy
  doi: 10.1586/eri.11.79
– volume: 2016
  start-page: 1465
  issue: 95
  year: 2016
  ident: 10.7717/peerj.18475/ref-25
  article-title: Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era
  publication-title: Annals of Hematology
  doi: 10.1007/s00277-016-2742-7
– volume: 68
  start-page: 105
  issue: 1
  year: 1975
  ident: 10.7717/peerj.18475/ref-27
  article-title: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(75)80054-0
– volume: 90
  start-page: 1306
  issue: 7
  year: 2004
  ident: 10.7717/peerj.18475/ref-31
  article-title: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
  publication-title: British Journal of Cancer
  doi: 10.1038/sj.bjc.6601699
– volume: 56
  start-page: 1710
  issue: 6
  year: 2015
  ident: 10.7717/peerj.18475/ref-15
  article-title: Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant
  publication-title: Leukemia & Lymphoma
  doi: 10.3109/10428194.2014.941833
– volume: 18
  start-page: 6196
  issue: 6
  year: 2019
  ident: 10.7717/peerj.18475/ref-6
  article-title: Hepatitis B virus infection and 1q21 amplification in multiple myeloma
  publication-title: Oncology Letters
  doi: 10.3892/ol.2019.10926
– volume: 92
  start-page: E611
  issue: 10
  year: 2017
  ident: 10.7717/peerj.18475/ref-1
  article-title: Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: a study based on the nationwide Danish multiple myeloma registry
  publication-title: American Journal of Hematology
  doi: 10.1002/ajh.24857
– volume: 53
  start-page: 270
  issue: 2
  year: 2012
  ident: 10.7717/peerj.18475/ref-9
  article-title: High preva-lence of hepatitis B virus infection in multiple myeloma
  publication-title: Leukemia & Lymphoma
  doi: 10.3109/10428194.2011.610013
– volume: 11
  start-page: 1819
  issue: 11
  year: 2019
  ident: 10.7717/peerj.18475/ref-24
  article-title: Reactivation of hepatitis B virus in patients with multiple myeloma
  publication-title: Cancers
  doi: 10.3390/cancers11111819
– volume: 5
  start-page: 272
  issue: 3
  year: 2017
  ident: 10.7717/peerj.18475/ref-23
  article-title: Emerging trends in epidemiology of hepatitis B virus infection
  publication-title: Journal of Clinical and Experimental Hepatology
  doi: 10.1016/j.jceh.2015.06.002
– volume: 29
  start-page: 516
  year: 2017
  ident: 10.7717/peerj.18475/ref-16
  article-title: Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B
  publication-title: Annals of Oncology
  doi: 10.1093/annonc/mdx694
– volume-title: R: a language and environment for statistical computing
  year: 2022
  ident: 10.7717/peerj.18475/ref-21
– volume: 27
  start-page: 605
  issue: 4
  year: 2009
  ident: 10.7717/peerj.18475/ref-29
  article-title: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
  publication-title: Journal of Clinical Oncology
  doi: 10.1200/JCO.2008.18.0182
– volume: 35
  start-page: 2363
  issue: 11
  year: 2015
  ident: 10.7717/peerj.18475/ref-14
  article-title: Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy
  publication-title: Liver International
  doi: 10.1111/liv.12838
– volume: 138
  start-page: 563
  issue: 5
  year: 2007
  ident: 10.7717/peerj.18475/ref-20
  article-title: Immunodeficiency and immunotherapy in multiple myeloma
  publication-title: British Journal of Haematology
  doi: 10.1111/j.1365-2141.2007.06705.x
– volume: 49
  start-page: S156
  issue: 5 Suppl
  year: 2019
  ident: 10.7717/peerj.18475/ref-8
  article-title: Reactivation of hepatitis B
  publication-title: Hepatology
  doi: 10.1002/hep.22945
– volume: 20
  start-page: 693
  issue: 4
  year: 2016
  ident: 10.7717/peerj.18475/ref-13
  article-title: Hepatitis B and risk of non-hepatocellular carcinoma malignancy
  publication-title: Clinics in Liver Disease
  doi: 10.1016/j.cld.2016.06.005
– volume: 16
  start-page: 609
  issue: 6
  year: 2015
  ident: 10.7717/peerj.18475/ref-5
  article-title: Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells
  publication-title: Nature Immunology
  doi: 10.1038/ni.3159
– volume: 111
  start-page: 2516
  issue: 5
  year: 2008
  ident: 10.7717/peerj.18475/ref-12
  article-title: Improved survival in multiple myeloma and the impact of novel therapies
  publication-title: Blood
  doi: 10.1182/blood-2007-10-116129
– volume: 36
  start-page: 84
  issue: 1
  year: 2012
  ident: 10.7717/peerj.18475/ref-19
  article-title: Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy
  publication-title: Clinics and Research in Hepatology and Gastroenterology
  doi: 10.1016/j.clinre.2011.07.018
– volume: 62
  start-page: 299
  year: 2000
  ident: 10.7717/peerj.18475/ref-30
  article-title: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors
  publication-title: Journal of Medical Virology
  doi: 10.1002/(ISSN)1096-9071
– volume: 11
  start-page: 552
  year: 2020
  ident: 10.7717/peerj.18475/ref-22
  article-title: Liver, tumor and viral hepatitis: key players in the complex balance between tolerance and immune activation
  publication-title: Frontiers in Immunology
  doi: 10.3389/fimmu.2020.00552
– volume: 7
  start-page: 631
  issue: 12
  year: 2017
  ident: 10.7717/peerj.18475/ref-26
  article-title: Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan
  publication-title: Blood Cancer Journal
  doi: 10.1038/s41408-017-0002-2
– volume: 90
  start-page: E73-4
  issue: 4
  year: 2015
  ident: 10.7717/peerj.18475/ref-7
  article-title: Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: astudy based on the nationwide Danish myeloma database
  publication-title: American Journal of Hematology
  doi: 10.1002/ajh.23932
– volume: 49
  start-page: 1211
  issue: 8
  year: 2009
  ident: 10.7717/peerj.18475/ref-17
  article-title: Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents
  publication-title: Clinical Infectious Diseases
  doi: 10.1086/605664
– volume: 18, 36
  start-page: 266
  issue: 4
  year: 2019
  ident: 10.7717/peerj.18475/ref-3
  article-title: Hepatitis B reactivation rate and fate among multiple myeloma patients receiving regimens containing lenalidomide and/or bortezomib
  publication-title: Turkish Journal of Hematology
  doi: 10.4274/tjh.galenos.2019.2019.0103
– volume: 22
  start-page: 393
  issue: 2
  year: 2016
  ident: 10.7717/peerj.18475/ref-28
  article-title: Chemokine expression profiles of human hepatoma cell lines mediated by hepatitis B virus X protein
  publication-title: Pathology & Oncology Research
  doi: 10.1007/s12253-015-0014-9
– volume: 42
  start-page: 627
  issue: 7
  year: 2012
  ident: 10.7717/peerj.18475/ref-18
  article-title: Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
  publication-title: Hepatology Research
  doi: 10.1111/j.1872-034X.2012.00998.x
– volume: 121
  start-page: 749
  year: 2003
  ident: 10.7717/peerj.18475/ref-11
  article-title: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
  publication-title: British Journal of Haematology
  doi: 10.1046/j.1365-2141.2003.04355.x
SSID ssj0000826083
Score 2.3325982
Snippet Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage e18475
SubjectTerms Adult
Aged
Bortezomib - therapeutic use
Female
Gastroenterology and Hepatology
Health aspects
Hematology
Hepatitis B - drug therapy
Hepatitis B - virology
Hepatitis B Surface Antigens - blood
Hepatitis B virus
Hepatitis B virus - physiology
Humans
Infectious Diseases
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Multiple Myeloma - virology
Oncology
Prevention
Prognosis
Reactivation
Retrospective Studies
Risk Factors
Statistics
Virology
Virus Activation
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6btu01aFQE8mfsiW1FtSGkIhpYcGchN6jMhC1g5eb2GhP74jyV7W9NBLj7YGY2le36B5EHLieWML7kSOUVuTM174XELrc1NWXLqqNizWVl19by-v2beb5uZg1FfICUvtgdPBnZoGSsc8SNe2zHmL_rXkoqh0w11b-li6hz7vIJiKNhhRM4KLVJDHMWQ5vQcY0C6gMW4WLih26v_bHh84pGWy5IH3uXhCHk-wkZ6l331KHkD3jDy8mi7Gn5PfP4Y-pMytNrT39BZCnvSID-f012rYbihCQzsPMqOrjiKYvttRl_LswNE5r5Cud3DXr3WgWccxaRQGTVOV1u4z1filcejn-kwau9O-INcXX39-ucynwQq5bQo25oYJdOO-8rYpbW2KutYgQWhvwSAi0oU1peWV8-jiWFno0KZVttK20kuPfKhfkqOu7-A1oQh_HOjSC20BY0NtZBjdVBsBjoPmLCMn81mr-9Q_Q2HcEViiIktUZElGzgMf9iSh6XV8gaKgJlFQ_xKFjHwIXFSpgnSvuupMhBtsgYFuRj5FiqC8yEyrpxoE3Etog7WgPF5QotLZxfLHWVJUWAqZah30242qETChnCNuzMirJDn7XdWSyRDhZkQsZGqx7eVKt7qNPb_LgMtl0b75Hwf1ljyqEJulkspjcjQOW3iH2Go076Ma_QGpViX7
  priority: 102
  providerName: Directory of Open Access Journals
Title Prognosis of hepatitis B virus reactivation in newly diagnosed multiple myeloma in modern era therapy: a retrospective study
URI https://www.ncbi.nlm.nih.gov/pubmed/39498289
https://www.proquest.com/docview/3124127125
https://pubmed.ncbi.nlm.nih.gov/PMC11533906
https://doaj.org/article/b5e1d4fe9d664dfc89317802a57d61f9
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEB6VVkJcEG9cSlikSpxc_Fh7vVxQg1oqpFQVIlJuq_U-aKTELk5SEYkfz-zajmrgwCVSspPHemZ2volnvgE4tixTEdNFiFlbFlIW2ZCb3IZlnDCuk7SkvrdqcplfTOmXWTbbg34YZ3cBV_9M7dw8qWmzOPn5Y_sRHR7x6wnDbOT9jTENujyes9k9OMCQxJyHTjqc749kBNGRp-RMHM83og7e9ur9-f5BdPIk_n8f1Xdi1bCO8k5gOn8EDztESU5bE3gMe6Z6Avcn3T3zp_DrqqldNd18RWpLro0roV7jkzG5nTebFUHUqPoZZ2ReEcTZiy3RbQme0aQvOSTLrVnUS-lkln6CGjGNJG0D1_YDkfhJ66buWzeJJ659BtPzs2-fLsJu5kKosoiuw5IWGOFtYlUWq7SM0lQabgpplSkRLMlIlbFiibYY_WgcScfgynOucm651QhfnsN-VVfmJRBERtrI2BZSGUwbZcndVKe0LIxmRjIawHF_rcVNS60hMCVxKhFeJcKrJICx08NOxPFh-xfq5rvo3EuUmYk1tYbjT6DaKkRhMSuiRGZM43Z4AG-cFkXbXLrzanFauJvbBebAAbzzEs7SUJlKdu0JuBfHkDWQPBpIoj-qwfLb3lKEW3JFbJWpNyuRIpZCF0BIGcCL1nJ2u0o55S75DaAY2NRg28OVan7t6cBjB9l5lB_-xxe_ggcJorK2mfII9tfNxrxGVLUuR3AwPru8-jry_0rg4-dZPPJe9BvhmSdK
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognosis+of+hepatitis+B+virus+reactivation+in+newly+diagnosed+multiple+myeloma+in+modern+era+therapy%3A+a+retrospective+study&rft.jtitle=PeerJ+%28San+Francisco%2C+CA%29&rft.au=Lv%2C+Weiran&rft.au=Li%2C+Xiaojin&rft.au=Xu%2C+Jingbo&rft.au=Wang%2C+Yun&rft.date=2024-11-01&rft.issn=2167-8359&rft.eissn=2167-8359&rft.volume=12&rft.spage=e18475&rft_id=info:doi/10.7717%2Fpeerj.18475&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2167-8359&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2167-8359&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2167-8359&client=summon